1,3,5-Trimethyl-pyrrolidon-(2) | 89895-20-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1,3,5-Trimethyl-pyrrolidon-(2)
• 英文别名: 1,3,5-trimethyl-pyrrolidin-2-one；1,3,5-Trimethylpyrrolidin-2-one
• CAS: 89895-20-5
• 化学式: C₇H₁₃NO
• 分子量: 127.186
• InChiKey: ZBLCKMSVDNMPLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• DIHYDROPYRROLOPYRIMIDINE DERIVATIVES
  申请人：PFIZER INC.

  公开号：US20150291604A1

  公开（公告）日：2015-10-15

  The present invention relates to compounds of formula (X) or pharmaceutically acceptable salts thereof, wherein R 1 -R 50 , a, b, d, e, f, g, h, i, j, k, l, o, p, q, r, s, t, u, y, and z are defined herein. The novel dihydropyrrolopyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（X）化合物或其药学上可接受的盐，其中R1-R50，a，b，d，e，f，g，h，i，j，k，l，o，p，q，r，s，t，u，y和z在此定义。这种新型二氢吡咯吡咪啉衍生物在哺乳动物的异常细胞生长，如癌症治疗中有用。其他实施例涉及含有该化合物的制药组合物以及在哺乳动物中治疗异常细胞生长的方法。
• [EN] CHROMONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES DE CHROMONE INHIBITEURS DE METALLOPROTEINASE DE MATRICE
  申请人：WARNER LAMBERT CO

  公开号：WO2004014880A1

  公开（公告）日：2004-02-19

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, y2, y3, Y4, U5, U6, U8, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically 10 acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MW-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MNIP 13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由式I或其药学上可接受的盐所定义的化合物，其中R1、Q、y2、y3、Y4、U5、U6、U8和R2如规范中所定义。本发明还提供了药物组合物，包括由规范中定义的式I或其药学上可接受的盐所定义的化合物，以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了抑制动物中MW-13酶的方法，包括向动物注射式I或其药学上可接受的盐所定义的化合物。本发明还提供了治疗由MNIP 13酶介导的疾病的方法，包括向患者注射式I或其药学上可接受的盐所定义的化合物，单独使用或与药物组合物一起使用。本发明还提供了治疗患有心脏病、多发性硬化症、骨关节炎和类风湿性关节炎以外的其他关节炎、心力衰竭、炎症性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺疾病、哮喘、牙周疾病、银屑病、动脉硬化和骨质疏松症的方法，包括向患者注射式I或其药学上可接受的盐所定义的化合物，单独使用或与药物组合物一起使用。本发明还提供了组合物，包括由规范中定义的式I或其药学上可接受的盐所定义的化合物，以及规范中描述的另一种药学活性成分。
• Compositions for treating used rubber and their use in a recycling process
  申请人：SIXTH WAKOOL PTY. LTD.

  公开号：EP0008916A1

  公开（公告）日：1980-03-19

  Used rubber is treated for recycling by placing it in a mixture containing one or more optionally substituted benzenes (e.g. toluene or xylene) until it is brittle, followed preferably by removal from the mixture and pulverizing it. The mixture can contain also one or more C4 to Clo alkanes or alkenes and/or optionally substituted pyrrolidones. Preferred inclusive ranges by weight are: optionally substituted benzenes 40 - 80%, alkanes or alkenes 1 - 20%, and optionally substituted pyrrolidones 0 - 40%. A typical composition for use in the treatment is, by weight, 88% toluene, 6% xylene, 3% methylpyrrolidone and 3% iso-octane.

  将废旧橡胶放入含有一种或多种任选取代的苯（如甲苯或二甲苯）的混合物中直至其变脆，然后将其从混合物中取出并粉碎，即可对其进行回收处理。 混合物中还可含有一种或多种 C4 至 Clo 烷烃或烯和/或任选取代的吡咯烷酮。 按重量计，优选的包含范围为：任选取代的苯 40-80%，烷烃或烯 1-20%，任选取代的吡咯烷酮 0-40%。 按重量计，用于处理的典型成分为：88%甲苯、6%二甲苯、3%甲基吡咯烷酮和 3%异辛烷。
• SUBSTITUTED IMIDAZOHETEROCYCLES
  申请人：Cara Therapeutics, Inc.

  公开号：EP2170350B1

  公开（公告）日：2013-09-11
• US4782078A
  申请人：——

  公开号：US4782078A

  公开（公告）日：1988-11-01